SCHEMBL20766835

SCHEMBL20766835

CC(C)(C)NS(=O)(=O)c1ccc(F)c(C#N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.50
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 4/20 0.47
PARG Q86W56 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
MAPK1 P28482 1/20 0.47
HSP90AA1 P07900 2/20 0.45
HSP90AB1 P08238 2/20 0.45
SLC22A12 Q96S37 2/20 0.43
SGK1 O00141 2/20 0.43
ALOX5AP P20292 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10153815 0.83 ACLY (0.53) ACLYSMN1; SMN2LMNAALDH1A1HSP90AA1
SCHEMBL20988223 0.80 KMT2A (0.56) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL1793139 0.80 MEN1 (0.49) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL15358865 0.80 ACLY (0.56) ACLYHSP90AA1HSP90AB1SLC22A12SGK1
SCHEMBL3115416 0.79 SMN1; SMN2 (0.45) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL15574395 0.79 ACLY (0.50) ACLYALDH1A1HSP90AA1HSP90AB1SLC22A12
SCHEMBL3363359 0.77 RORC (0.45) ACLYHSP90AA1HSP90AB1SLC22A12SGK1
SCHEMBL12327372 0.77 EPAS1 (0.55) ACLYHSP90AA1HSP90AB1SLC22A12PTGDR2
SCHEMBL15867026 0.77 ACLY (0.49) ACLYMEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL21190881 0.76 KMT2A (0.51) MAPTSMN1; SMN2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542315-B Benzosulfonyl compounds 维瓦斯治疗公司 2023-05-12 CN disclosed
EP-3691623-B1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS INC (US) 2022-10-05 EP disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
CN-111542315-A Benzosulfonyl compounds 维瓦斯治疗公司 2020-08-14 CN disclosed
EP-3691623-A1 BENZOSULFONYL COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-08-12 EP disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 ACLY 1990/4885MAPT 2341/4885SMN1; SMN2 2357/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 ACLY 1990/4885MAPT 2341/4885SMN1; SMN2 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.